Navigation Links
World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval

SAN DIEGO, Feb. 28, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of high-performance specialty enzymes, today announced that Terminal 6, a major producer of soybean meal, oil and biodiesel, has successfully begun use of Verenium's Purifine enzymatic degumming process at its Puerto General San Martin facility in Argentina. Purifine enzymatic degumming is a novel process that significantly increases yields in edible oil production and can have additional benefits in refining the Purifine-degummed oil.

"Terminal 6 is a leading processor of soybeans, and a flagship plant for Bunge Argentina and Aceitera General Deheza," said Janet Roemer, President and Chief Operating Officer of Verenium.  "Verenium is pleased to be able to work with Terminal 6 to enable enhanced operating efficiency through the use of Purifine PLC. This implementation provides further validation of Verenium's Purifine technology to increase oil yields and improve the efficacy of meal production, and has been enabled by our partnerships with Alfa Laval and Bunge."

"Implementation of the Purifine PLC enzymatic degumming process has resulted in a significant increase in oil yields and processing margins enabling our facility to more fully reach its potential," said Enrique Humanes, Chief Executive Officer, Bunge Argentina.  "Successful installation of this process shows Bunge Argentina's continued commitment to leading edge process technologies that provide economic and environmental benefits."

"The implementation of Verenium's PLC technology at Terminal 6 combined with Alfa Laval's process, engineering and equipment supply capabilities, is the second large scale project we have completed together," said Bent Sarup,  General Manager of Alfa Laval's Vegetable Oil Technology activities. "Completion of the start up of Terminal 6's new process is further validation of our ongoing partnership with Verenium."

The Terminal 6 industrial facility has been built to take advantage of large-scale process efficiencies that enable maximum yields of oil and meal from soybeans at low cost. Integration of Verenium's enzyme further improves the plant performance because the oil loss in the enzyme-based process is lower than in non-enzymatic processes.

About PurifineVerenium's patented and novel Purifine enzyme facilitates improved operating efficiency and reduction in byproducts by allowing a higher percentage of the crude vegetable oil extracted from seeds to be recovered and converted into edible oil or biodiesel. In conventional processing phospholipid impurities are removed as emulsified gums with an associated oil yield loss. Purifine enzyme works by reacting with the phospholipids releasing both the oil entrained in the gum and the oil-component of the phospholipids. Compared to other degumming methods, oil yield losses are reduced by up to 75% using Purifine enzymatic degumming, depending on the phospholipid content of the oil. Purifine PLC can also offer significant benefits to the refining process by improving operating efficiency, and reducing the need for harsh chemicals and other processing aids.

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries including the global food and fuel markets.  Read more at

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:Kelly Lindenboom

Vice President, Corporate Communications


Sarah Carmody

Manager, Corporate Communications


SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ansell Launches Worldss First Antimicrobial Surgical Glove
2. BioSpace Highlights One of the Nations Largest Life Science Regions
3. LSU researchers awarded 1 of the largest NSF grants in Louisiana history
4. All-New Sermo Brings Major Enhancements to Nations Largest Online Physician Community
5. CardioCareLive, the Largest Online Cardiology Conference, Attracts 2,300 Attendees and Enjoys 92% Recommendation Rate
6. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
7. Beike Biotechnology Opens Worlds Largest Stem Cell Storage and Processing Facility
8. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
9. Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies
10. Nations Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate
11. DONG Energy and Inbicon Inaugurate One of the Worlds Largest Demo Plants for 2nd Generation Biofuel
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):